Nippon Shinyaku Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
788.1K | +8.75% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
509.6K | +12.42% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
355.1K | 0.00% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
202.2K | +24.81% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
177.0K | +3.87% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
162.1K | 0.00% |
Dividend History
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥124 | 0.0% |
| 2024 | ¥124 | +4.2% |
| 2023 | ¥119 | +2.6% |
| 2022 | ¥116 | +14.9% |
| 2021 | ¥101 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥137,484M | ¥144,175M | ¥148,255M | ¥160,232M |
| Gross Profit | ¥87,293M | ¥88,195M | ¥98,021M | ¥109,115M |
| Operating Income | ¥32,948M | ¥30,050M | ¥33,297M | ¥35,451M |
| Pretax Income | ¥33,420M | ¥30,625M | ¥33,945M | ¥36,280M |
| Net Income | ¥24,986M | ¥22,812M | ¥25,851M | ¥32,558M |
| EPS | ¥370.97 | ¥338.70 | ¥383.82 | ¥483.40 |
| Operating Margin | 23.96% | 20.84% | 22.46% | 22.12% |
| Balance Sheet | ||||
| Total Assets | ¥219,943M | ¥237,451M | ¥263,404M | ¥283,637M |
| Total Equity | ¥180,584M | ¥195,624M | ¥220,224M | ¥247,027M |
| Total Liabilities | ¥39,359M | ¥41,827M | ¥43,180M | ¥36,610M |
| Cash | ¥60,566M | ¥60,047M | ¥58,094M | ¥55,241M |
| Interest-bearing Debt | ¥2,713M | ¥2,664M | ¥2,872M | ¥2,722M |
| Equity Ratio | 82.10% | 82.38% | 83.61% | 87.09% |
| D/E Ratio | 0.02 | 0.01 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥21,316M | ¥26,170M | ¥16,289M | ¥36,126M |
| Investing CF | -¥10,037M | -¥17,631M | -¥9,921M | -¥28,877M |
| Financing CF | -¥8,407M | -¥9,605M | -¥9,719M | -¥9,902M |
| Free CF | ¥12,373M | ¥14,442M | ¥6,640M | ¥1,333M |
| Efficiency | ||||
| ROE | 13.84% | 11.66% | 11.74% | 13.18% |
| ROA | 11.36% | 9.61% | 9.81% | 11.48% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4516
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥6,200
Rating Score: - (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Nippon Shinyaku Shares Surge as Analyst Target Soars on Clinical Breakthrough - AD HOC NEWS ↗
MVP: Latham's Mike Morin - Law360 ↗
Company Information
About
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.